Synthesis of PF-6870961, a major hydroxy metabolite of the novel ghrelin receptor inverse agonist PF-5190457

This publication has 8 references indexed in Scilit:

• Endocrine effects of the novel ghrelin receptor inverse agonist PF-5190457: Results from a placebo-controlled human laboratory alcohol co-administration study in heavy drinkers
  Neuropharmacology, 2020
• Development and validation of an assay for a novel ghrelin receptor inverse agonist PF-5190457 and its major hydroxy metabolite (PF-6870961) by LC-MS/MS in human plasma
  Journal of Chromatography B, 2019
• Role of Molybdenum-Containing Enzymes in the Biotransformation of the Novel Ghrelin Receptor Inverse Agonist PF-5190457: A Reverse Translational Bed-to-Bench Approach
  Drug Metabolism and Disposition, 2019
• Ghrelin: From a gut hormone to a potential therapeutic target for alcohol use disorder
  Physiology & Behavior, 2019
• The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study
  Molecular Psychiatry, 2018
• The Role of the Ghrelin System in Drug Addiction
  2017
• Pharmacokinetics and pharmacodynamics of PF‐05190457: The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects
  British Journal of Clinical Pharmacology, 2016
• Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate
  ACS Medicinal Chemistry Letters, 2014